FALL 2013 DIGITAL EDITION< /span>. CLICK HERE TO READ
Fluorescence Lifetime Assays.
Gene Editing: Re-writing genomes with targetable nucleases.
The great neuro-pipeline "brain drain"(and why Big Pharma hasn’t given up on CNS disorders).
Oousourced Kinase Profiling Services: adding value to in-house kinase programmes.
Automated compound management evolves to meet the drug discovery demands of the future.
Biomarker discovery: the need for new generation peptideprotein microarrays.
Evolving strategies for application-specific validation of research use antibodies. .
SPRING 2013 DIGITAL EDITION. CLICK HERE TO READ
Realising the genomes potential in the context of the living cell.
Evolution of flow cytometry as a drug screening platform..
DNA sequencing towards the third generation and beyond.
Chemical space, HTS and the world of blockbuster drugs..
Challenges and opportunities in the treatment of rare diseases.
Addressing the economic downturn through Lab Instrument Rental.
An automated approach to solving Pharmas cardiac toxicity conundrum.
Adoption of high content screening at HTS laboratories..
WINTER 2012/13 DIGITAL EDITION. CLICK HERE TO READ
Transforming data into better healthcare.
T cell epitope identification by mass spectrometry: the future in detail.
Induced Pluripoint stem cells in high-throughput cellular screening.
Diverging paths, difficult choices.
Fragrement library design: the evolution fragment-based lead discovery.
Cell migration: probing cell movementwith smarter tools.
Carbon-14 labelled API manufacturing.
FALL 2012 DIGITAL EDITION. CLICK HERE TO READ
Saved by the BEL - ringing in a common language for the life sciences
Targeting tau for Alzheimers disease and related neurodegenerative disorders.
The challenges of the changing drug discovery model.
ELISA ASSAYS: recent innovations take analyte detection to new levels.
Meeting the challenge of healthcare- associated infections with new antimicrobials.
Metabolomics - analytic methods driving exponential understanding.
Asian innovation – a unique opportunity.
SUMMER 2012 DIGITAL EDITION. CLICK HERE TO READ
Innovate while derisking drug development – yes we can!
In vivo imaging in drug development: Gamma Scintigraphy.
New tools increase accessibility to HCS Assays.
Editing the human genome: role in functional genomics and translational medicine.
Stem cells, cell-based assays and the world of small molecules.
Pharmaceutical and biomedical research likely to use $1 billion worth of microfluidics devices by 2016.
The application of iPS cells and differentiated neuronal cells to advance drug discovery.
SPRING 2012 DIGITAL EDITION. CLICK HERE TO READ
Biological analysis and interpretation for improved research outcomes.
Collaborative research leads to new understanding of BIOMARKERS.
Optimising well results in label-free analysis.
The Information Symphony: data orchestration for a changing industry.
A life sciences powerhouse: ONTARIO, Canada’s story.
WINTER 2011 DIGITAL EDITION. CLICK HERE TO READ
Simultaneous visualisation of attrition and timelines: funnel diagrams.
SMALL-SCALE BENCHTOP AUTOMATION: broadening the adoption of lab automation.
STEM CELL differentiation.
Exploring the horizons of small molecule drug discovery:the evolution and application of the ideal fragment library
The apocalyptic horsemen of drug discovery and development
When High Content Screening meets High Throughput
A roadmap for achieving self-sustainability of academic high throughput screening core facilities.
FALL 2011 DIGITAL EDITION. CLICK HERE TO READ
DNA diagnostics gets digitised.
SMAC MIMETICS a new class of targeted agents that activate apoptotic cell death and block pro-survival signalling in cancer cells.
Combining chemists’ expertise and a computer’s advanced capabilities to generate ‘good’ ideas.
EPIGENETICS targeting the mediator between environment and phenotypePATHWAY ANALYSIS: understanding the bridge between environmental cues and cellular response.
A life sciences powerhouse: ONTARIO Canada’s story.
STEM CELL BANKS: investing in the promise of cancer stem cell science.
SUMMER 2011 DIGITAL EDITION. CLICK HERE TO READ
Selecting a LIMS for next-generation sequencing research
What are the obstacles to innovation in the pharmaceutical industry?
The need for high throughput kinetics early in the drug discovery process.Keeping ahead of the flow
In Vivo Preclinical Imaging: an essential tool in translational research
In Vivo Cell Reprogramming: current status and potential clinical applications
Early patient stratification is critical to enable effective and personalised drug discovery and development
The Sooner the Better: utilising biomarkers to eliminate drug candidates with cardiotoxicity in preclinical development
SPRING 2011 DIGITAL EDITION. CLICK HERE TO READ
3D Cell culture
Balancing a Biologics
The Benefits of drug repositioning.
The future of molecular diagnostics for cancer: a ‘personalised’ perspective.
The post genomics Era: what does it all mean and how can we translate it?
Regenerative Medicine: a paradigm shift in healthcare.
Enabling the promise of stem cells
Winter 2010 Digital Edition. CLICK HERE TO READ
New ways to optimise therapeutic and diagnostic antibodies;
Assessing the value of R&D partnerships.
Protein biomarker immunoassays opportunities and challenges.
Making early access real.
HTS SYSTEMS: impact of reliability on downtime and drug discovery.
Moving forward with label-free technology.
R&D open verdict?
Induced pluripotent stem cells a model for transforming drug discovery
Fall 2010 Digital Edition. CLICK HERE TO READ
Overcoming Bottlenecks in Drug Discovery
Bulk Reagent Dispensers - ubiquitous liquid handling
High throughput flow cytometry for discovery at UNMCMD and the NIH Molecular Libraries Initiative.
Current trends in label-free technologies
Mass Spectrometry in Drug Discovery and Development.
Neutron scattering provides unique insights for drug R&D
New mechanisms and expanded indications for biologic therapies: a perspective on immunology research and development
Is the pharmaceutical industry open for innovation?
Summer 2010 Digital Edition CLICK HERE TO READ
Tracking HTS Assay Development Time - opportunity for improving drug discovery
Enterprise ELNs as a foundation for preclinical drug development
Biomarkers make their mark on current research and drug development trends.
3D Cell Culture - easier said than done!
New Trends and Therapeutic Approaches for the Management of Diabetic Retinopathy.
Flourescence Lifetime - finally picking up momentum!
Companion Diagnostics in the pharmaceutical industry- -part II: business models.
Personalised Medicine - market and regulatory landscape.
Spring 2010 Digital Edition CLICK HERE TO READ
Utilising 3D nuclear DNA methylation patterns in cell-based assays for epigenetic drug screening
Towards unbiased biomarker discovery.
Overview of Companion Diagnostics in the pharmaceutical industry.
Compound Profiling: size impact on primary screening libraries.
Real-Time PCR: where we are and where are we heading.
Stem Cells: for cellular therapy space.
The healthcare industry’s evolving role in translational research an opportunity for competitive advantage
Recent advances in HCS Laser Scanning Cytometry.
Winter 2009 Digital Edition CLICK HERE TO READ
Singapore Strengthens Position as Leading Site for Biopharmaceutical R&D
Leveraging Research Informatics to Accelerate Drug Discovery
Maximising the Impact of Technologies on Drug Discovery through Portfolio Management.
Integrating Computational Methods and Drug Discovery – avoiding pitfalls in chemical space.
Innovation in Drug Discovery Technology.
Free Online Resources Enabling Crowd-sourced Drug Discovery.
Design Of Experiments - useful statistical tool in assay development or vendor disconnect!
Custom Carbon-14 Radiolabelling.
Fall 2009 Digital Edition CLICK HERE TO READ
1536 Progress - Done Deal but Difficult Transition?
Harnessing Fragment-based Drug Discovery at CRT
Structure-Based Drug Design will crystallisation ‘chaperones’ make all proteins crystallisable?
A Perspective on Scientific Innovation in the Pharmaceutical Industry.
The growth of personalised medicine will drive alliances between diagnostic and pharmaceutical industries.
Multiplexing for Biological Relevance in High Throughput Screening.
Molecular Imaging Approaches